Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RMC-9805 + TNG462 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RMC-9805 | RMC 9805|RMC9805 | KRAS G12D Inhibitor 25 | RMC-9805 inhibits KRAS G12D, which potentially results in reduced downstream signaling and proliferation, induction of apoptosis, and decreased tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 526). | |
| TNG462 | TNG 462|TNG-462 | PRMT5 Inhibitor 21 | TNG462 is a PRMT5 inhibitor with selectivity for MTAP-deleted cells, which may decrease tumor growth (European J Cancer 174, 2022 (suppl 1, S84)). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06922591 | Phase Ib/II | Daraxonrasib + TNG462 RMC-9805 + TNG462 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Recruiting | USA | 0 |